ARS director granted options on 30,000 SPRY shares
ARS Pharmaceuticals director Kelly Michael received a stock option grant for 30,000 shares of common stock at an exercise price of $10.54 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ARS Pharmaceuticals director Kelly Michael received a stock option grant for 30,000 shares of common stock at an exercise price of $10.54 per share. The option expires on June 23, 2036 and will vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Kelly Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Key Figures
Option grant size: 30,000 options
Exercise price: $10.54 per share
Shares underlying options: 30,000 shares
+3 more
6 metrics
Option grant size
30,000 options
Stock Option (right to buy) granted to director Kelly Michael
Exercise price
$10.54 per share
Exercise price for 30,000-share stock option grant
Shares underlying options
30,000 shares
Common Stock underlying the derivative award
Post-grant derivative holdings
30,000 options
Total derivative securities held after this transaction
Option expiration
June 23, 2036
Expiration date of the stock option grant
Vesting date trigger
Earlier of June 24, 2027 or 2027 meeting
Full vesting of the 30,000-share option
Key Terms
Stock Option (right to buy), exercise price, expiration date, annual meeting of stockholders
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 10.5400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ARS Pharmaceuticals (SPRY) director Kelly Michael report?
Director Kelly Michael reported receiving a stock option grant for 30,000 shares of ARS Pharmaceuticals common stock. The option is a compensation-related award, not an open-market purchase, and gives the right to buy shares at a fixed exercise price in the future.
What is the exercise price of the ARS Pharmaceuticals (SPRY) options granted to Kelly Michael?
The options granted to Kelly Michael have an exercise price of $10.54 per share. This means he can buy up to 30,000 ARS Pharmaceuticals shares at $10.54 regardless of future market price, once the options are vested and exercisable.
When do Kelly Michael’s ARS Pharmaceuticals (SPRY) options vest?
The 30,000-share option grant vests in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual stockholder meeting. Until that vesting event, the options generally cannot be exercised for common shares.
When do the ARS Pharmaceuticals (SPRY) options granted to Kelly Michael expire?
The stock options granted to Kelly Michael expire on June 23, 2036. If they are not exercised by that date, the right to purchase up to 30,000 ARS Pharmaceuticals common shares at $10.54 per share will lapse and become worthless.
Is Kelly Michael’s ARS Pharmaceuticals (SPRY) Form 4 a stock buy or a compensation grant?
The Form 4 reflects a compensation grant, not an open-market stock purchase. Kelly Michael received 30,000 stock options for ARS Pharmaceuticals as a director award, giving a future right to buy shares at a fixed exercise price.
How many ARS Pharmaceuticals (SPRY) derivative securities does Kelly Michael hold after this grant?
After this grant, Kelly Michael holds 30,000 derivative securities in the form of stock options. Each option is linked to one share of ARS Pharmaceuticals common stock, contingent on vesting and subject to the stated expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
